EFM-192A 人乳腺癌細(xì)胞
Catalogue No.: C1003
Product Format: a T25 flask
Culture Properties：貼壁
Complete Growth Medium: 89%H-DMEM+10%FBS+1%雙抗
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Application: Cells and cancer research
NOTE: FOR RESEARCH USE ONLY.

Components

September 2019 and achieved SD for months, but progressed at September 2020. EP regimen was stopped and changed to CAPTEM regimen, but the disease still progressed in March 2021. Since a high CD8+ TILs in?ltration (hotspot: 3325 cells/mm2) was present in this patient’s T-NEN specimen, immunotherapy with toripalimab was initiated since April 2021.